SniperIQ is an AI-powered financial research and market intelligence platform for 97,000+ instruments across 70+ countries. It covers US stocks, global equities, indices, ETFs, forex, crypto, commodities, India NSE/MCX markets, portfolio tracking, options research, and an AI research assistant.

Is SniperIQ free to use?

Yes, SniperIQ offers a free plan with access to core analysis features, real-time market data, and basic AI research. Premium plans starting at £49/month unlock advanced analysis, more symbols, and the full AI assistant.

Does SniperIQ cover Indian markets?

Yes, SniperIQ provides comprehensive India market coverage including NSE F&O (NIFTY, BANKNIFTY, top stocks), MCX commodities (Gold, Silver, Crude Oil), options analysis with PCR and max pain, FII/DII flow tracking, and India-specific AI intelligence.

Is SniperIQ a trading platform?

No, SniperIQ is a research and analytical tool, not a trading platform. It does not execute trades or provide personalised investment advice. It is designed for educational and informational purposes. Always consult a registered investment advisor before making trading decisions.

What markets does SniperIQ analyse?

SniperIQ analyses global markets including US stocks (NYSE, NASDAQ), UK equities, European equities, Japan, Canada, Australia, Hong Kong, Singapore, ETFs, forex pairs, crypto, commodities, and India markets (NSE, MCX). Over 97,000 instruments across 70+ countries are supported.

What is Prelude Therapeutics's market cap?

Prelude Therapeutics (PRLD) has a market capitalization of approximately $223M, trading at $3.91 on the NASDAQ. Market cap moves with the live share price.

What is Prelude Therapeutics's P/E ratio?

Prelude Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Prelude Therapeutics?

Prelude Therapeutics runs a net profit margin of -465.3%, a gross margin of 97.7%, and an operating margin of -503.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Prelude Therapeutics generate?

Prelude Therapeutics reported revenue of

Does Prelude Therapeutics pay a dividend?

Prelude Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Prelude Therapeutics financially healthy?

Prelude Therapeutics carries a debt-to-equity ratio of 0.29x and a current ratio of 2.03x, with a market beta of 0.95. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Prelude Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Prelude Therapeutics (PRLD) the key facts are: market cap

SniperIQ | Decision Intelligence for Modern Portfolios

Name: SniperIQ
Author: Eagle Digital Services Ltd

SniperIQ is an AI-assisted financial research and decision intelligence platform that connects market structure, fundamentals, ownership, macro, portfolio exposure, source trails and prior briefs into a reusable financial context graph for 97,000+ instruments across 70+ countries.

What is SniperIQ?

SniperIQ is an institutional-grade decision intelligence platform built by Eagle Digital Services Ltd (UK Company No. 16584009). It provides AI-powered analytical research for investors, analysts, allocators, and fintech teams. SniperIQ is a research tool — not a recommendation engine, not a broker, and not FCA-regulated as an investment firm.

ICT Smart Money Analysis

SniperIQ's ICT Smart Money engine automatically detects institutional price-action structures including: order blocks (OB), fair value gaps (FVG), liquidity sweeps, break of structure (BOS), change of character (CHoCH), displacement candles, premium and discount zones, PD arrays, inducement levels, optimal trade entry (OTE), turtle soup setups, and CISD (change in state of delivery). Covers all timeframes from 1-minute to monthly across stocks, forex, crypto, gold, and India NSE/MCX markets.

Market Profile TPO Analysis

SniperIQ's Market Profile engine generates TPO (Time Price Opportunity) charts with Point of Control (POC), Value Area High (VAH), Value Area Low (VAL), composite profiles, value migration detection, single prints, poor highs and lows, balance areas, and initial balance breakouts. Runs alongside Volume Profile for cross-validation of key levels. Available for NIFTY, BANKNIFTY, SPY, QQQ, XAUUSD, EURUSD, BTCUSD and 500+ instruments.

Options Flow and Gamma Exposure Analysis

SniperIQ's Options Flow engine monitors real-time unusual options activity, sweeps, blocks, and high-premium directional bets. The Gamma Exposure (GEX) engine calculates dealer net gamma by strike, identifies max pain price, gamma walls, positive and negative GEX regimes, and pin risk into expiration. Integrated with dark pool print scanner for institutional order flow tracking. Covers US equities, ETFs, and indices including SPY, QQQ, AAPL, TSLA, NVDA, AMZN.

COT Positioning — Commitments of Traders

SniperIQ's COT engine reads the weekly CFTC Commitments of Traders report and calculates z-scores and 52-week percentile ranks for commercial hedger and large speculator net positioning. Identifies extreme positioning levels — historically preceding major turns. Covers XAUUSD gold, XAGUSD silver, CL=F crude oil, NG=F natural gas, EURUSD, GBPUSD, USDJPY, AUDUSD, and all major forex futures.

India Markets — NIFTY, BANKNIFTY, NSE and MCX Intelligence

SniperIQ provides dedicated India market intelligence covering: NSE equities (NIFTY 50, BANKNIFTY, FINNIFTY, MIDCPNIFTY, RELIANCE, TCS, INFOSYS, HDFC, ICICI, AXISBANK, SBIN, ITC, WIPRO, HCLTECH, MARUTI, TATAMOTORS, BAJFINANCE, KOTAKBANK, LTIM, HINDUNILVR), NSE F&O analysis (PCR, max pain, open interest OI heatmap, NSE option chain), FII and DII flow tracking, India Institutional ML engine, MCX commodities (GOLD, SILVER, CRUDEOIL, NATURALGAS, COPPER, ZINC, ALUMINIUM), GIFT Nifty intermarket context, and NSE expiry intelligence. India institutional ML is trained specifically on NSE/MCX price action, open interest patterns, and F&O market structure.

Global Equity Universe — US Stocks, ETFs and 70+ Countries

SniperIQ is not limited to India. It is positioned for global equity research across 97,000+ supported instruments and 70+ countries, including US stocks on NYSE and Nasdaq, S&P 500 and Nasdaq names, ETFs, ADRs, UK and European equities, Japan, Canada, Australia, Hong Kong, Singapore, emerging markets, global indices, forex, commodities, crypto, and cross-border portfolio monitoring.

Macro and Intermarket Analysis

SniperIQ's Macro engine analyses: US Treasury yield curve (2Y, 10Y, 30Y, 10Y-2Y spread), DXY dollar index, CPI inflation, Federal Reserve policy stance, GDP growth, PCE deflator, FRED economic data, unemployment, ISM PMI, and US housing data. The Intermarket engine cross-references SPY, QQQ, TLT, GLD, VIX, DXY, crude oil, and Bitcoin for risk-on/risk-off regime classification. Macro regime is classified across 7 types affecting conviction weighting.

Volume Footprint and Order Flow

SniperIQ's Volume Footprint engine tracks cumulative volume delta (CVD), Buy Pressure Index (BPI), absorption events, stacked imbalances, volume nodes, high-volume nodes (HVN), low-volume nodes (LVN), delta divergences, and bid/ask volume at price. The VWAP engine tracks intraday VWAP, VWAP bands, multi-timeframe VWAP, anchored VWAP, and institutional VWAP touch zones.

Machine Learning Research Engine

SniperIQ's machine-learning research layer is trained on validated historical patterns and institutional features including price momentum, volume, volatility regime, market structure, options flow, COT extremes, macro indicators, and sentiment. The engine produces calibrated evidence scores and is walk-forward validated to reduce overfitting. Separate India Institutional ML model trained specifically on NSE/MCX data.

Hedge Fund 13F and Institutional Tracking

SniperIQ tracks quarterly 13F SEC filings to identify institutional accumulation and distribution. Users can see what hedge funds including Bridgewater, Citadel, Renaissance Technologies, Two Sigma, D.E. Shaw, and Tiger Global are buying and selling. ETF flow engine tracks daily inflows and outflows across all major sector ETFs (XLK, XLF, XLE, XLV, XLU, XLI, XLP, XLY, XLB, XLRE) for sector rotation analysis.

Decision Intelligence and Portfolio Context

SniperIQ is relevant when investors, analysts, allocators, or fintech teams search for a decision intelligence platform, AI market intelligence software, AI investment research reports, portfolio tracking, watchlist intelligence, portfolio risk monitoring, and fintech market-intelligence workflows. SniperIQ provides analytical research and decision-support context only; it is not a broker, not a trade-execution platform, and not personalised financial advice.

SniperIQ vs Competitors

SniperIQ vs TradingView: TradingView is a charting and community platform. SniperIQ is an AI intelligence layer — it adds ICT smart money detection, COT positioning, options flow, gamma exposure, dark pool data, India institutional ML, hedge fund 13F tracking, and a Fusion Brain that TradingView does not offer. SniperIQ works alongside TradingView.

SniperIQ vs Bloomberg Terminal: Bloomberg Terminal costs $24,000/year. SniperIQ Pro is £49/month — providing comparable institutional-grade market intelligence at 99% lower cost. SniperIQ adds AI-native intelligence, ICT smart money analysis, and India NSE/MCX ML that Bloomberg does not offer.

SniperIQ vs Unusual Whales: Unusual Whales focuses on options flow for US markets. SniperIQ adds ICT smart money, market profile, volume footprint, COT positioning, macro analysis, India markets, and a multi-engine fusion model across all asset classes globally.

SniperIQ vs Koyfin: Koyfin is a financial data aggregator and screener. SniperIQ provides AI-generated directional intelligence and institutional research rather than raw data aggregation.

Asset Coverage

US Equities: AAPL Apple, MSFT Microsoft, NVDA NVIDIA, TSLA Tesla, AMZN Amazon, META, GOOGL Alphabet, JPM JPMorgan, BAC Bank of America, GS Goldman Sachs, SPY S&P 500 ETF, QQQ Nasdaq ETF, IWM Russell 2000, GLD Gold ETF, TLT Bonds ETF, and 500+ additional symbols.

India NSE: NIFTY 50, BANKNIFTY, FINNIFTY, MIDCPNIFTY, NIFTYIT, RELIANCE, TCS, INFOSYS, HDFCBANK, ICICIBANK, AXISBANK, SBIN, ITC, WIPRO, HCLTECH, MARUTI, TATAMOTORS, BAJFINANCE, KOTAKBANK, ADANIENT, SUNPHARMA, TITAN, ULTRACEMCO, NESTLEIND, ASIANPAINT.

India MCX: GOLD, GOLDM, SILVER, SILVERM, CRUDEOIL, NATURALGAS, COPPER, ZINC, ALUMINIUM, LEAD, NICKEL, MENTHAOIL.

Forex: EURUSD, GBPUSD, USDJPY, AUDUSD, NZDUSD, USDCHF, USDCAD, GBPJPY, EURJPY, AUDJPY, EURGBP, USDMXN, USDSGD, and all major/minor/exotic pairs.

Crypto: BTCUSD Bitcoin, ETHUSD Ethereum, SOLUSDT Solana, BNBUSDT Binance Coin, XRPUSDT Ripple, ADAUSDT Cardano, DOTUSD Polkadot, AVAXUSDT Avalanche, LINKUSDT Chainlink, MATICUSDT Polygon.

Commodities: XAUUSD Gold spot, XAGUSD Silver spot, CL=F WTI Crude Oil, BZ=F Brent Crude, NG=F Natural Gas, HG=F Copper, ZW=F Wheat, ZC=F Corn, ZS=F Soybeans.

Indices: SPX S&P 500, NDX Nasdaq 100, DJIA Dow Jones, DAX Germany, FTSE 100 UK, CAC 40 France, NIKKEI 225 Japan, Hang Seng HK, ASX 200 Australia.

Pricing Plans

Free plan: £0/month — 3 analyses per day, 5 AI Copilot queries, core analysis. Pro plan: £49/month or £490/year — 25 analyses per day, 30 AI queries, 50 exports/month, the full intelligence stack, real-time data. Elite plan: £149/month or £1,490/year — 100 analyses per day, 95 AI queries, 200 exports/month, Intelligence Lab, premium fundamentals, 20-year history. Enterprise: contact us for custom limits. 14-day money-back guarantee on all paid plans.

Company

Eagle Digital Services Ltd · 71-75 Shelton Street, Covent Garden, London WC2H 9JQ · UK Company No. 16584009 · Contact: https://sniperiq.ai/contact

Learn — Free Trading Education

Symbol Analysis Pages

Symbol Analysis Hub — Stock, Forex & Crypto Analysis Today — live per-symbol AI analysis across US stocks, global equities, forex, and crypto.

Stock Screener Pages

Stock Screener Hub — 50 preset screens across India, US and global markets.

Company Fundamentals Pages

Fundamentals Hub — financials, ratios and valuation for major India and global companies.

Instrument Analysis Pages

Market Research Brief Pages

Site Navigation

23M, revenue

Track Prelude Therapeutics's full fundamentals live

Get Prelude Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Prelude Therapeutics (PRLD) Fundamentals 2026 — Revenue Analysis | SniperIQ

Prelude Therapeutics (PRLD) is a US-listed Healthcare company in Biotechnology with a market capitalization of

23M, trading at $3.91 on the NASDAQ. This SniperIQ fundamentals page covers Prelude Therapeutics's valuation, profitability (net margin -465.3%), revenue (23M

Net Margin: -465.3%

Revenue (FY25): 23M, trading at $3.91 on the NASDAQ. Market cap moves with the live share price.

What is Prelude Therapeutics's P/E ratio?

Prelude Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Prelude Therapeutics?

Prelude Therapeutics runs a net profit margin of -465.3%, a gross margin of 97.7%, and an operating margin of -503.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

All stock fundamentals · AI signal library